Endocrine Therapy: Translational Research on CYP2D6 Genetics for Tamoxifen Response in Breast Cancer

The recent advances in tamoxifen pharmacogenetics have raised considerable interest in the clinical application of CYP2D6 genetic testing for the identification of breast cancer patients capable to benefit from tamoxifen and distinguish them from those in need for alternative endocrine treatment options. This work shows the evidence in favor of that notion and introduces our ongoing activities with respect to tackle the yet missing link of the correlation between the patient's CYP2D6 genotype, corresponding clinically active tamoxifen metabolite levels, and treatment outcome. Tamoxifen is considered an essential…